ICIs have been a hot topic in cancer treatment research in recent years, primarily targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in the body’s immune process (42). This evidence concerns the gene CD274 and cancer.